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Abstract: It has often been recognized that a discrepancy exists during the clinical consultation 
between the chronological age of a patient on the one hand with the signs and symptoms of 
biological age that can be recorded on the other hand. In cardiovascular medicine this is obvi-
ous when a heavy smoker presents with features of early biological aging, for example skin 
appearance and impaired lung function. This could also be extrapolated to vascular function as 
the target for numerous cardiovascular risk factors, thereby increasing the risk of early cardio-
vascular disease (CVD). Both new and old treatment modalities can play a role for the preven-
tion of early vascular aging, ﬁ  rst of all smoking cessation and improved lifestyle in general, 
but later on also the use of drugs such as statins or agents that block the renin – angiotensin 
system (RAS). New classes of drugs are currently being tested for CVD prevention, including 
glitazones and rimonabant, even if adverse effects (heart failure and depression) might restrict 
their usefulness. Results from ongoing intervention studies will eventually cast new light on 
possibilities to prevent the development of vascular aging.
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Cardiovascular risk in general is inﬂ  uenced by a number of risk factors and risk mark-
ers, some of them modiﬁ  able and possible to prevent, but other ones are nonmodiﬁ  able 
(Table 1). In subjects with a positive family history for cardiovascular disease (CVD) 
these risk factors or markers are often elevated as a result of genetic traits, eg, as medi-
ated via familiar hypercholesterolemia, or socio-cultural factors, such as smoking hab-
its, but not all of the risk is explained by conventional factors (Andersdottir et al 2002). 
There also seems to exist a special link between the risk of CVD in mothers and the 
corresponding risk in sons (Nilsson et al 2004; Sundquist and Li 2006), even adjusted 
for conventional risk factors in the offspring (Nilsson et al 2004). The causes for this 
association are largely unknown but could be complex. It is however well-known 
that a number of adverse psychosocial conditions and social stress can substantially 
inﬂ  uence the risk of CVD (Kaplan and Kiel 1993; Bairey et al 2002) and the clinical 
course of established disease and mortality, for example as recorded in people living 
in republics of the former Soviet Union (Plavinski et al 2003). One hypothesis to 
explain some aspects of early CVD in susceptible individuals is that of ongoing early 
cardio-vascular aging as part of a broader process of early biological aging (Nilsson 
1996; Adams and White 2004). This concept could be helpful not only to explain 
the shifting incidence and prevalence rates of CVD in societies facing varying social 
and socio-economic difﬁ  culties, but also offer testable hypothesis in both animal and 
human experiments or clinical investigations. One example of this research would be 
to ﬁ  nd novel long-term markers of the biological aging process, for example telomere 
length and corresponding telomerase activity (Aviv, 2003; Artandi 2006), even if the 
latter is normally highest in fetal life and early infancy – not in adulthood.Vascular Health and Risk Management 2008:4(3) 548
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What is vascular aging?
Normal vascular aging is associated with a gradual change 
of the vascular structure and function, resulting in decreased 
arterial compliance and increased arterial stiffening (Edward 
et al 2002; Laurent et al 2006). This is inﬂ  uenced by age-
dependent structural and biochemical changes, eg, in the 
content of elastin and collagen in the vessel wall. Superim-
posed on this more or less normal process is pathological 
arterial vascular aging (atherosclerosis) with characteristic 
lesions and plaque formation (Hansson 2005), starting with 
subtle increased intima media thickening (IMT) in the ves-
sel wall (Bots and Grobbee 2002). Another important aspect 
is the aging effects on impairment of endothelial-mediated 
vasodilatation and decrease in ﬁ  brinolysis.
In susceptible individuals the vascular aging process 
seems to take a more rapid course, eventually resulting in 
premature CVD manifestations, including coronary heart 
disease (CHD), myocardial infarction, stroke, and symptoms 
from peripheral arterial disease (PAD). Another aspect is the 
progressing vascular dementia with its clinical symptoms of 
impaired cognitive function, depression, and disturbed cen-
tral regulation of physiological processes, eg, blood pressure 
regulation. This early (premature) vascular aging (EVA) is 
both inﬂ  uencing a more rapid course of normal age-dependent 
arterial changes and the superimposed pathological vascular 
aging based on atherosclerosis (Najjar et al 2005). The process 
is measurable directly by use of imaging devices such as 
ultrasound measurements of the arterial wall, for example 
in the carotid artery, the aorta, or the femoral artery, for 
evaluation of IMT and plaque formation. Another approach 
is to use physiological methods such as pulse wave veloc-
ity (PWV) or the arterial augmentation index (AI) based 
on pulse wave analysis, as markers of arterial stiffening. In 
addition the ankle-brachial pressure can be used as a marker 
of decreased peripheral arterial circulation. Other methods 
include the measurements of different biomarkers reﬂ  ecting 
endothelial function (Jarvisalo et al 2006), as an important 
part of the vascular aging process, or the measurement of 
telomere length (Samani et al 2001), as outlined below. Some 
important features of EVA are listed in Table 2.
Telomere attrition and vascular 
aging
Telomeres are specialized chromatin structures that form 
the end cap of the DNA helix and are shortened by each 
cell division until the cell can divide no more. It has been 
repeatedly shown that telomere length, most often measured 
in peripheral blood cells is shorter (reﬂ  ecting so called 
“mitotic senescence”) in subjects with arterial aging, athero-
sclerosis, CHD, insulin resistance, impaired glucose toler-
ance and type 2 diabetes, or reporting poor lifestyle habits 
as reﬂ  ected in obesity and excessive smoking (Obana et al 
2003; Brouilette et al 2003; Ogami et al 2004; Benetso et al 
2004; Gardner et al 2005; Valdes et al 2005; Cherkas et al 
2006; Adaikalakoteswari et al 2007; Fitzpatrick et al 2007; 
Fuster et al 2007). Even psychosocial stress exposure has 
been shown to be associated with shorter telomere length 
(Epel et al 2004), as well as with increased risk of CVD 
(Kaplan and Keil 1993; Bairey et al 2002). Telomere length 
Table 1 Major modiﬁ  able and nonmodiﬁ  able risk factors for 
cardiovascular disease






Elevated LDL – cholesterol







Poor sleep and relaxation
Adverse fetal growth pattern




Medical history of CVD or diabetes
Family history of CVD or diabetes
Table 2 Features of early vascular ageing (EVA)
  •  Increased arterial stiffness and pulse wave velocity
  •  Impaired endothelial function and vasodilatation
  •  Chronic vascular inﬂ  ammation
  •  Intima media thickness and early atherosclerosis
  •  Hemorheological disturbances of blood ﬂ  ow
  •  Capillary rarefaction and dysfunctional regulation
  •  Shorter telomere length/lower telomerase activity
  •  Impaired glucose and lipid metabolism
 •  Insulin  resistance
 •  Oxidative  stress
 •  Arterial  calciﬁ  cation
  •  Increased deposition of matrix substances
  •  Small vessel degeneration in brain and kidney
  •  Increased left ventricular heart (LVH) load with hypertrophyVascular Health and Risk Management 2008:4(3) 549
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is even a predictor of mortality risk in subjects aged 60 years 
or older (Cawthon et al 2003). No studies, however, have so 
far been able to show time-dependent changes in telomere 
length in relation to changes in vascular function or ultra-
sound imaging of arterial wall characteristics, for example 
the IMT, after repeated measurements. This could represent 
a fruitful approach in future studies of vascular changes in 
relation to age that is supposed to be heterogeneous in sub-
jects at different CVD risk. Recently it was reported from the 
WOSCOP trial in middle-aged Scottish men that treatment 
with pravastatin reduced the risk of coronary heart disease 
associated with shorter telomeres (Brouilette et al 2007).
Other molecular mechanisms 
associated with aging
During mitochondrial metabolic activity, reactive oxidative 
species (ROS) are produced and increase the oxidative stress 
burden. This will negatively impact on aging processes, 
including the potential for DNA repair function. External 
causes for increased ROS will add to this, by the inﬂ  uence of 
smoking and certain aspects of food processing.
Current activities to characterize the genetic background 
for type 2 diabetes, based on so called whole genome scan 
approach (DGI 2007), will hopefully also shed light on the 
relationship with diabetes complications. Some of these 
complications, as inﬂ  uenced by hyperglycemia and other risk 
factors, could also be regarded as examples of early aging in 
poorly controlled diabetes.
In pre-hypertension and established hypertension the 
renin – angiotensin system (RAS) is often activated. It has been 
shown that induction of angiotensin II (Ang II), one important 
factor in the RAS activation, also promotes a cell growth 
arrest with phenotypic characteristics of cell senescence, 
such as enlarged cell shapes, increased senescence-associated 
beta-galactosidase positive staining cell, and depressed cell 
proliferation. Apoptotic changes are increased in senescent 
cells. The results from one experimental study suggested that 
cell apoptosis is possibly an important factor in the process 
of pathologic and physiologic senescence of endothelial cells 
as well as vascular aging (Shan et al 2007). This means that 
pharmacological agents blocking RAS and Ang II activity 
could theoretically slow down vascular aging processes.
Investigations in a population-based 
cohort from SWEDEN
One aspect of age-related changes in vascular structure is the 
development of IMT that can also be promoted by the inﬂ  uence 
of risk factors such as systolic blood pressure. Therefore, 
IMT could be a surrogate marker for structural changes in the 
arterial vessel wall that resembles aging effects.
In the population-based Malmö Diet Cancer – Cardiovascular 
(MDC-CV) cohort study, from the city of Malmö in southern 
Sweden, we have access to ultrasound measurement of IMT, 
plaque prevalence rate, and estimation of carotid blood ﬂ  ow 
in over 6013 middle-aged men and women investigated at 
baseline in 1992–1995. Previous publications have reported on 
cross-sectional associations between the degree of IMT on the 
one hand with measures of insulin resistance (Hedblad et al 
2000) or markers of inﬂ  ammation and glucose metabolism, 
such as adiponectin (Nilsson et al 2006), on the other hand. 
Follow-up studies of the MDC-CV cohort have shown the 
predictive power of IMT for the incidence of stroke (Rosvall 
et al 2005a) and CHD (Rosvall et al 2005b). Increased IMT, 
reﬂ  ecting early atherosclerosis, could also partly explain the 
link between low social class and low educational level with 
cardiovascular risk (Rosvall et al 2000, 2006). We currently 
do follow-up investigations after a mean duration of 14-years 
since the baseline investigation. Some of these subjects have, 
however, been treated pharmacologically for various risk 
factors and medical conditions in the meantime, a factor that 
has to be taken into account and adjusted for in all statistical 
analyses. One randomized controlled intervention study in 
a subgroup of MDC-CV showed the beneﬁ  ts of low-dose 
metoprolol for slowing of the IMT progression; the BCAPS 
study (Hedblad 2001). In another randomized, controlled 
intervention trial the effect of the insulin sensitizing agent 
rosiglitazone was tested for slowing of IMT progression in 
subjects with type-2 diabetes or the insulin resistance syn-
drome (Hedblad et al 2007). In summary, the MDC-CV cohort 
offers interesting possibilities to further elucidate on the 
phenomenon of early vascular aging in relation to biological, 
lifestyle-related, and psychosocial risk factors. Investigations 
of genetic markers, telomere length, and arterial stiffness 
(pulse wave velocity, AI) are other research options currently 
being explored in this cohort, similar to the ASKLEPIOS 
Study in Belgium (Rietzschel et al 2007).
The role of diabetes in early aging
The incidence of type-2 diabetes typically increases with 
age, due to age-related changes in beta-cell function and 
insulin sensitivity, in conjunction with lowered physi-
cal activity and increase in body weight and relative fat 
mass. Increasing levels of hyperglycemia are associated 
with early CVD events (Danaei et al 2006), and this could 
be due either to the impact of hyperglycemia per se or 
its determinants (eg, insulin resistance) or consequences Vascular Health and Risk Management 2008:4(3) 550
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(advanced glycosylation end products; AGE). The risk could, 
however, also be a consequence of the impact of various CVD 
risk factors associated with hyperglycemia (insulin resistance), 
eg, dyslipidemia, elevated blood pressure, defects in ﬁ  brinoly-
sis, chronic low-grade inﬂ  ammation, etc. (Stamler et al 1993). 
It is therefore not unexpected that subjects with type-2 diabe-
tes mellitus also experience an elevated CVD risk, relatively 
more pronounced in women than in men with diabetes (Hu 
et al 2005). For these well proven reasons established diabetes 
can be regarded as a model of early biological aging with 
accompanying early vascular aging that can be seen as both 
macro- and microvascular manifestations. In a few cases, even 
longstanding diabetes can however be encountered without 
severe complications, as described in the so-called “Golden 
Years Project” in the UK (Bain et al 2003). This could be a 
manifestation of either protective genes for example regulation 
of HDL cholesterol metabolism via enzymes such as CETP, 
healthy lifestyle, or effects of medical care and compliance 
with anti-diabetes treatment, eg, insulin therapy.
The role of AGE for arterial stiffening is important, as 
this is a mechanisms related to the glycosylation in many 
various proteins in different organs, thus explaining stiffening 
of not only vascular tissue but also for example lung tissue 
in relation to the effects of hyperglycemia.
How to prevent early vascular 
aging?
In subjects with increased risk and a positive family history 
of early manifestations of CVD it is advisable to screen 
for and treat all conventional risk factors such as smoking, 
hypertension, hyperlipidemia and impaired glucose tolerance 
or type 2 diabetes, according to current guidelines (Graham 
et al 2007). Smoking is a deleterious risk factor, not only for 
coronary heart disease in a dose-response fashion according 
to the INTERHEART study (Teo et al 2006), but also for 
vascular dysfunction in general and the risk of increased 
insulin resistance and type 2 diabetes (Rimm et al 1995). New 
pharmacological treatment alternatives, for example use of 
the partial nicotine receptor-agonist varenicline (Jorenby et al 
2006), might help smokers to quit their deleterious nicotine 
dependence. Lifestyle improvements in general (physical 
exercise and a balanced diet) are also useful components for 
cardiovascular protection, as shown for fruit and vegetables 
and modest alcohol intake in the INTERHEART study. This 
should be applied to many people with conventional risk 
factors below cut-off levels in current guidelines, eg, for 
blood pressure, cholesterol or glucose, of increased arterial 
stiffness is present, being one marker of vascular aging. 
Other evidence-based treatment modalities include the use of 
ACE-inhibitors for prevention of CVD manifestations based 
on atherosclerosis in risk patients (Dagenais et al 2006), as 
well as statin therapy (CTT 2005), according to recent large 
meta-analyses. One interesting possibility is that treatment 
with pravastatin seems to reduce the risk for coronary heart 
disease events in middle-aged men with short telomeres, as 
described in the WOSCOP trial (Brouilette et al 2007). It is 
still largely unproven if the angiotensin-2 (AT1) receptor 
blockers (ARB) can offer the same, more, or less vascular 
protection as compared to the more studied class of ACE-
inhibitors (Dagenais et al 2006). However, in the large-scale 
ONTARGET trial, more than 25,000 subjects with hyper-
tension and associated risk factors have been randomized to 
treatment either by the ACE-inhibitor ramipril or the ARB 
telmisartan, or to the combination of the two drugs, for pre-
vention of fatal and nonfatal CVD endpoints (Teo et al 2004). 
This trial is of substantial clinical importance and expected 
to be presented in 2008.
The treatment of diabetes and its hyperglycemia should 
be based on a new treatment algorithm presented in 2006 by 
ADA and EASD (Nathan et al 2006), including a ﬁ  rst step 
of lifestyle modiﬁ  cation in combination with metformin. As 
an optional second step the use of insulin, sulphonylurea or 
glitazones can be advocated by appropriate need. How to 
work for a strict CVD risk factor control in all patients with 
diabetes is outlined in another example of new joint guide-
lines from the ESC/EASD in Europe (Rydén et al 2007). If 
all these preventive measures could be effectively applied, the 
risk of early (cardio-) vascular aging could be counteracted 
and the progression slowed in these high-risk patients.
Conclusions
The concept of early (premature) vascular aging (EVA) rep-
resents a potentially fruitful model for future research into 
pathophysiological mechanisms behind early manifestations 
of CVD. For example, more research is needed to elucidate 
on the gene-environment interaction behind vascular and 
endothelial dysfunction, eg, the interaction between the 
genetic determinant of nitric oxide production in the endo-
thelial wall by nitric oxide synthetase (eNOS) in relation to 
smoking exposure (Leeson et al 2002). We also need a more 
thorough evaluation of different markers of early vascular 
aging for CVD risk prediction: Such markers could include 
different measures of arterial stiffness, a hallmark of early 
vascular aging in combination with endothelial dysfunction 
as evident in some patients with hypertension (Taddei et al 
1997). New biomolecular markers such as telomere length Vascular Health and Risk Management 2008:4(3) 551
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(Aviv 2002) have to be evaluated in various intervention 
studies, both with lifestyle advice and with speciﬁ  c drug 
therapy. Such potentially beneﬁ  cial drugs not only include 
well-established drugs for vascular protection like statins 
and ACE-inhibitors, but also newer drugs such as ARB, 
the endocannaboid receptor (CB1) antagonist rimonabant, 
and the PPAR-activating glitazones, even if some adverse 
effects (heart failure) could caution against a wide use of 
the latter class of drugs. Examples of randomized controlled 
trials exploring cardiovascular protection of these newer 
compounds include ONTARGET for ARB (Teo et al 2004), 
CRESCENDO for rimonabant (CRESCENDO 2005), and 
RECORD for rosiglitazon (Home et al 2005). During 2007 
the revision of guidelines for cardiovascular prevention was 
published (Graham et al 2007). It is still an open question if the 
concept of early vascular aging will be directly addressed or 
not in future guidelines, but the risk factors contributing to this 
condition and their evidence-based treatment will certainly be. 
A larger question to solve is to understand and prevent many 
of the adverse psychosocial risk factors, and their lifestyle 
correlates that might speed up the process of early biological 
aging in general (Nilsson 2003; Chandola et al 2006). This is 
a question of efforts in public health policy making (Marmot 
2006), and not a matter of drug treatment.
Finally, all physicians should educate their patients to 
healthy lifestyle to prevent or delay vascular aging, cardio-
vascular diseases, and to maintain a good quality of life and 
thereby increase their life expectancy.
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